Live feed16:05:00·29dPRReleasevia QuantisnowTravere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA NephropathyByQuantisnow·Wall Street's wire, on your screen.TVTX· Travere Therapeutics Inc.Health Care
